...s.r.l. named Mathieu Simon as chairman and Julia Berretta as CEO. Simon is chairman of Lysogene S.A....

...DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT); prodrug company Ascendis Pharma A/S (NASDAQ:ASND); CNS-focused gene therapy company Lysogene S.A....

...Rett syndrome and the University of Florida for cardiomyopathy and multiple sclerosis; a deal with Lysogene S.A....

...in preclinical development: Axovant Sciences Ltd. has AXO-AAV-GM1, an AAV9 vector encoding wild-type GLB1; and Lysogene S.A....
...and Institutions Mentioned Alector Inc., South San Francisco, Calif. Axovant Sciences Ltd. (NASDAQ:AXGT), Basel, Switzerland Lysogene S.A....

...of multiple deals by Sarepta to build out its gene therapy pipeline, including partnerships with Lysogene S.A....

...of multiple deals by Sarepta to build out its gene therapy pipeline, including partnerships with Lysogene S.A....

...in Lysogene, which is also eligible for up to $125 million in milestones, plus royalties. Lysogene...
...sale of 950,606 shares at $2.63 per share. The price is a 49% premium to Lysogene's...
...SGSH; HNS). Lysogene S.A. (Euronext:LYS), Neuilly-sur-Seine, France Sarepta Therapeutics Inc. (NASDAQ:SRPT), Cambridge, Mass. Business: Endocrine/Metabolic Alicia Parker LYS-SAF302, LYS-SAF-302 Lysogene S.A. Sarepta...

...protein responsible for Fragile X syndrome. The partners said first results are expected in 2019. Lysogene S.A....
...Conectus Alsace, Illkirch, France Business: Gene therapy, Neurology Shannon Lehnbeuter Institute of Genetics and Molecular and Cellular Biology Lysogene S.A. Fragile...